<DOC>
	<DOCNO>NCT02402998</DOCNO>
	<brief_summary>A clinical study evaluate efficacy drug call eltrombopag adult patient affect primary immune thrombocytopenia first treatment address disease .</brief_summary>
	<brief_title>Eltrombopag Second Line Adult Primary Immune Thrombosytopenia</brief_title>
	<detailed_description>This prospective , multicenter phase II trial design evaluate activity Eltrombopag second line treatment adult patient primary Immune Thrombocytopenia ( ITP ) responsive relapse full first line steroid treatment ( prednisone dexamethasone ) ± Intravenous Immune Globulin ( IVIG ) .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Diagnosis primary ITP ; 2 . Age ≥ 18 year ; 3 . Patients new diagnosis persistent phase disease ( i.e . within month 12 diagnosis ) ; 4 . Patients responsive relapse full course steroid therapy ( prednisone 1 mg/kg/d least 28 day 3 cycle dexamethasone 40 mg/day consecutive 4 day , accord GIMEMA ITP0207 trial ) ± IVIG ; 5 . Patients platelet count &lt; 10 x 109/L document single blood cell count ; 6 . Patients bleed symptom platelet count &gt; 10 &lt; 30 x 109/L documented single blood cell count ; 7 . Patients bleed symptom platelet count &gt; 10 &lt; 30 x 109/L least 2 blood cell count 3 day interval week precede enrollment last count day enrollment ; 8 . Patients corticosteroid IVIG dependence ( need ongoing repeat dos administration corticosteroid IVIG maintain platelet count ≥ 30 x 109/L and/or avoid bleeding ; 9 . Written inform consent obtain subject ; 10 . Men female partner childbearing potential must either prior vasectomy agree use effective contraception time enrollment 6 month last dose study treatment ; 11 . Female subject nonchildbearing potential may enrol study ; study population , nonchildbearing potential define current tubal ligation , hysterectomy , ovariectomy postmenopause ; OR 12 . Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior start Eltrombopag , negative pregnancy test within 14 day first dose Eltrombopag , agree continue adequate contraception entire treatment period 6 month completion treatment . 1 . Diagnosis secondary ITP . As far patient immune thrombocytopenia antiphospholipid antibody positivity , individual without previous thromboembolic event exclude lupus anticoagulant ( LAC ) associate presence anticardiolipin ( aCL ) aβ2Glycoprotein I ( aβ2GPI ) antibodies ; 2 . Previous treatment antiITP second line therapy ( i.e . Rituximab , Azathioprine , CyclosporinA ) ; patient previous full course steroid ( see inclusion criterion definition ) ± IVIG admit study ; 3 . Previous treatment TPOR agonists ; 4 . Patients life threaten bleeding complication ; 5 . Patients deep venous thrombosis ( DVT ) arterial thrombosis 3 month precede enrollment ; 6 . Patients HIV , HCV , HBsAg positive ; 7 . Patients hepatic impairment ( i.e . mild , moderate severe hepatic impairment ( ChildPugh score &gt; 6 ) ; 8 . Patients well establish liver disease represent contraindication use Eltrombopag ; 9 . Patients unable respect 4hour interval Eltrombopag medication ( e.g . antacid ) , calciumrich food ( e.g . dairy product calcium fortify juice ) , supplement contain polyvalent cation iron , calcium , aluminium , magnesium , selenium , zinc ; 10 . Patients unable stop medication know cause drugdrug interaction Eltrombopag ; 11 . Subjects meet follow criterion must enrol Eltrombopag study : Lactating female . History another malignancy . Exception : subject diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Any serious and/or unstable preexist medical , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure . Hormone replacement therapy . Subjects must discontinue hormone replacement therapy prior study enrollment due potential inhibition Cytochrome P450 ( CYP ) enzymes metabolize estrogen progestin . Administration investigational drug within 30 day 5 halflives , whichever longer , precede first dose study treatment . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate Eltrombopag excipients contraindicate participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primacy immune thrombocytopenia</keyword>
	<keyword>Adults</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Long-term remission</keyword>
</DOC>